CEO Feldschuh Buys 1,000 Shares of Daxor Corp at $9.07 – Insider Confidence Signals Bullish Outlook

Insider Buying Continues at Daxor Corp

The latest director‑dealing filing shows Chief Executive Officer Michael Richard Feldschuh purchasing 1,000 shares of Daxor common stock on April 8, 2026 at $9.07 per share. The purchase brings his ownership to 213,694 shares—roughly 41 % of the 520,000 shares outstanding—after a steady accumulation over the past two years (buying 2,063 shares in April 2025 and 1,000 shares in March 2024). The transaction price is close to the current market price of $9.38, suggesting a neutral valuation stance. Importantly, the deal occurs amid a spike in social‑media buzz (10.74 %) but a neutral sentiment score, indicating that investors are watching but not reacting strongly to the CEO’s activity.

What This Means for Investors

A CEO’s continued buying signals confidence in the company’s near‑term prospects, especially given Daxor’s recent launch of a blood‑volume‑analysis service and its FDA‑cleared technology. The 4.21 % weekly gain and 18.24 % yearly return reinforce that the stock is gaining traction. However, the company’s 52‑week high of $14.76 and a 52‑week low of $7.10 imply that volatility remains high. Investors should view Feldschuh’s purchase as a bullish cue, but also monitor cash flow from the new service and any regulatory developments that could affect reimbursement or market penetration.

A Profile of Feldschuh’s Insider Activity

Feldschuh’s purchase pattern is characterized by consistent, sizable buying blocks at modest prices, often around the mid‑$8 to $9 range. His most recent acquisition (April 2025) was 2,063 shares at $7.89, followed by a 1,000‑share purchase at $8.13 in March 2024. This disciplined buying approach—coupled with a 41 % ownership stake—suggests a long‑term commitment to Daxor’s growth strategy. The CEO’s hands‑on involvement in product launches and expansion plans is reflected in his willingness to invest his own capital, potentially aligning management and shareholder interests.

Company‑wide Insider Activity

Other executives have also been active: Chief Financial Officer Michel Robert J purchased 3,000 shares in December 2025 and 1,000 shares in March 2026, while Chief Medical Officer John Jefferies bought 3,656 shares (March 2026) and 2,285 shares (March 2026) at zero price—likely via a stock‑option exercise. The collective insider buying indicates a broader confidence among leadership in the company’s trajectory. Yet, the high volume of options and the absence of any significant selling suggests that the current valuation may still be below perceived intrinsic value.

Bottom Line for the Market

Feldschuh’s latest purchase, set against a backdrop of steady insider buying and a recent product launch, provides a subtle but credible bullish signal. The company’s strong fundamentals—low P/E of 4.88, a growing market for chronic‑disease volume management, and a 52‑week high of $14.76—suggest that Daxor could continue to climb if reimbursement and adoption accelerate. Investors should keep an eye on quarterly earnings, the success of the Ohio cardiology program, and any regulatory updates that could either bolster or undermine the company’s competitive edge.